Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 11, 2023eJHaemOpen Access

PET‐based radiomics signature can predict durable responses to CAR T‐cell therapy in patients with large B‐cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

MLMarta LigeroStratasys (Israel)MSMarc SimóVall d'Hebron Hospital UniversitariCCCecilia CarpioUniversitat Autònoma de Barcelona

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Ligero et al. (2023) studied this question.

synapsesocial.com/papers/6a8288f8d7a462ab0d8ad567https://doi.org/10.1002/jha2.757
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification2014 · 5,746 citations
  2. 2The 2016 revision of the World Health Organization classification of lymphoid neoplasms2016 · 7,965 citations
  3. 3Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma2017 · 6,114 citations
  4. 4Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma2020 · 428 citations
  5. 5Value of CT-Textural Features and Volume-Based PET Parameters in Comparison to Serologic Markers for Response Prediction in Patients with Diffuse Large B-Cell Lymphoma Undergoing CD19-CAR-T Cell Therapy2022 · 15 citations